KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Short term Debt (2020 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Short term Debt for 9 consecutive years, with $31.1 million as the latest value for Q4 2025.

  • Quarterly Short term Debt fell 34.41% to $31.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.1 million through Dec 2025, down 34.41% year-over-year, with the annual reading at $31.1 million for FY2025, 34.41% down from the prior year.
  • Short term Debt for Q4 2025 was $31.1 million at Supernus Pharmaceuticals, up from $11.2 million in the prior quarter.
  • The five-year high for Short term Debt was $78.4 million in Q1 2023, with the low at $11.2 million in Q3 2025.
  • Average Short term Debt over 5 years is $39.4 million, with a median of $45.9 million recorded in 2023.
  • The sharpest move saw Short term Debt skyrocketed 146.54% in 2023, then crashed 75.88% in 2025.
  • Over 5 years, Short term Debt stood at $44.8 million in 2021, then tumbled by 52.9% to $21.1 million in 2022, then surged by 146.54% to $52.1 million in 2023, then fell by 9.08% to $47.3 million in 2024, then crashed by 34.41% to $31.1 million in 2025.
  • According to Business Quant data, Short term Debt over the past three periods came in at $31.1 million, $11.2 million, and $30.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.